Cytokinetics (CYTK) Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Nasdaq ends lower as oil prices surge ahead of earnings, economic data
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
| CYTOKINETICS (NASDAQ: CYTK) | Delayed: 62.81 -0.1 (0.16%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $62.91 | 52 Week High | $13.18 | |||
| Open | $62.48 | 52 Week Low | $6.00 | |||
| Day High | $63.50 | P/E | N/A | |||
| Day Low | $62.13 | EPS | $-1.24 | |||
| Volume | 908,741 | |||||
